Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03190603|
Recruitment Status : Completed
First Posted : June 19, 2017
Last Update Posted : June 6, 2018
Axial Spondyloarthritis (SpA) is a kind of inflammatory arthritis which includes ankylosing spondylitis. Common symptoms of axial SpA are inflammatory back pain, morning stiffness, peripheral arthritis, enthesitis. Controlling aforementioned symptoms are one of the goal in treatment, and another goal is preventing bony ankylosis of axial skeleton such as spine. Ankylosis can limit range of motion and lower the quality of life.
Non-steroidal antiinflammatory drug (NSAID) and Tumor necrosis factor (TNF)-a inhibitor are the current treatment options for axial SpA. These medications can improve pain and stiffness of axial SpA patients, however preventing bony ankylosis is not proven. Current study showed attenuating inflammation at early stage could prevent further bony destruction and ankylosis in axial SpA. Present study is designed to discover the therapeutic effect of NSAID whether NSAID could recover the early inflammatory bony change (bone marrow edema at MRI) and prevent further bony change.
|Condition or disease||Intervention/treatment||Phase|
|Spondylarthropathies Magnetic Resonance Imaging||Drug: Celecoxib||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding|
|Actual Study Start Date :||June 1, 2018|
|Actual Primary Completion Date :||June 5, 2018|
|Actual Study Completion Date :||June 5, 2018|
Experimental: Celecoxib arm
Axial Spondyloarthritis patients who takes celecoxib 400mg for day
Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
- Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score of sacroiliac joint [ Time Frame: Baseline, 6 weeks after, 12 weeks after ]Change from baseline SPARCC MRI score of sacroiliac joint at 6 weeks and 12 weeks
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03190603
|Korea, Republic of|
|Armed Forces Capital Hospital|
|Seongnam-si, Korea, Republic of, KS009|